Get the latest news, insights, and market updates on VIVS (VivoSim Labs, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing marketSAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Aug 14, 2025 - $VIVS
VivoSim: Fiscal Q1 Earnings Snapshot
SAN DIEGO (AP) — VivoSim Labs, Inc. VIVS) on Tuesday reported a loss of $2.8 million in its fiscal first quarter. On a per-share basis, the San Diego-based company said it had a loss of $1.14. Aug 12, 2025 - $VIVS
Nio Inc. (NIO) umbles 8% as Slow July Deliveries Growth Disappoint
We recently published 10 Stocks Bleeding Early. NIO Inc. (NYSE:NIO) is one of the companies that stood stronger last week. Nio Inc. dropped its share prices by 8.18 percent on Monday to close at $4.6 apiece as investors soured on the slower growth in vehicle deliveries last month. In a statement on Friday, NIO Inc. (NYSE:NIO) said […] Aug 5, 2025 - $VIVS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.